Patents by Inventor Jeffrey A. Ecsedy

Jeffrey A. Ecsedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250064824
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: June 3, 2024
    Publication date: February 27, 2025
    Inventors: Jeffrey A. Ecsedy, Mengkun Zhang
  • Patent number: 12042499
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 23, 2024
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Ecsedy, Mengkun Zhang
  • Publication number: 20200397799
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: April 2, 2020
    Publication date: December 24, 2020
    Inventors: Jeffrey A. Ecsedy, Mengkun Zhang
  • Patent number: 10213436
    Abstract: Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane-based chemotherapy, such as paclitaxel or docetaxel.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 26, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Ecsedy, Wen Chyi Shyu, Arijit Chakravarty, Robert W. Kleinfield, Kha N. Le, Karthik Venkatakrishnan
  • Publication number: 20180207173
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: July 20, 2016
    Publication date: July 26, 2018
    Inventors: Jeffrey A. Ecsedy, Mengkun Zhang
  • Publication number: 20160193224
    Abstract: Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane-based chemotherapy, such as paclitaxel or docetaxel.
    Type: Application
    Filed: September 3, 2015
    Publication date: July 7, 2016
    Inventors: Jeffrey A. Ecsedy, Wen Chyi Shyu, Arijit Chakravarty, Robert W. Kleinfield, Kha N. Le, Karthik Venkatakrishnan
  • Publication number: 20040235071
    Abstract: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 and 13249 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions.
    Type: Application
    Filed: December 16, 2003
    Publication date: November 25, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Eric S. Lightcap, Jeffrey A. Ecsedy, John J. Hunter, Kyle J. MacBeth, Michelle Tighe Nestor